Key Takeaways
- Researchers identified 15-PGDH as an aging-linked enzyme influencing cartilage regeneration.
- Inhibition of 15-PGDH regenerated thicker cartilage with greater glycosaminoglycan content.
- PGDHi treatment improved cartilage regeneration following injury in mouse osteoarthritis models.
- 15-PGDH inhibition shifted chondrocytes toward extracellular-matrix production without increasing proliferation.
Osteoarthritis treatment today is built around managing what a damaged joint can no longer do. Exercise and physical therapy help preserve movement and strength; weight management can reduce load on weight-bearing joints; medicines and injections can relieve pain; and advanced disease may ultimately lead to joint replacement. These approaches can improve life with osteoarthritis, but they do not restore the articular cartilage that has been lost.
That leaves a fundamental question for regenerative medicine: could the cells already living inside damaged cartilage be persuaded to repair the tissue again?
A new Science study provides evidence pointing in that direction. Researchers identified an aging-linked enzyme, 15-hydroxyprostaglandin dehydrogenase (15-PGDH), whose inhibition regenerated articular cartilage in aged mice. The same strategy also improved cartilage regeneration after joint injury and produced regenerative changes in human osteoarthritis cartilage studied outside the body. The significance is not simply that more cartilage appeared. The experiments suggest that cells already living in damaged cartilage can be shifted toward a state associated with tissue maintenance and repair.
The problem researchers were trying to solve
Articular cartilage is the smooth tissue covering the ends of bones inside a joint. Its extracellular matrix gives it the strength and resilience needed to distribute mechanical loads and allow low-friction movement. Chondrocytes, the cells embedded in this matrix, normally maintain the tissue. With aging and osteoarthritis, however, cartilage loses its ability to maintain and repair itself effectively.
The researchers looked at 15-PGDH because its expression increased in the articular cartilage of aged and injured mice. In 24-month-old mice, 15-PGDH expression was about twice that seen in 4-month-old mice. 15-PGDH breaks down prostaglandins including PGE2 and PGD2. The researchers therefore tested whether inhibiting the enzyme could increase prostaglandin signaling and restore a more cartilage regeneration environment. They used the small-molecule inhibitor SW033291, referred to in the study as PGDHi.
Aged mice and cartilage regeneration
Aged mice treated with PGDHi developed thicker cartilage and greater glycosaminoglycan content than untreated aged mice. They also showed lower cartilage-damage scores using the OARSI scoring system. The regenerated tissue showed increased collagen II and other markers associated with articular cartilage. The findings indicated regeneration of tissue with characteristics of hyaline articular cartilage.
The researchers then tested the approach in a mouse model of post-traumatic osteoarthritis. After an injury that induces osteoarthritis, mice received PGDHi by intra-articular injection twice a week for four weeks. Treatment showed cartilage regeneration, reduced cartilage damage and preserved cartilage matrix. The treated mice also showed improvements in several pain-related and behavioral measures, including mechanical sensitivity and pressure-pain testing. This was important because it showed that the effect was not limited to naturally aged cartilage. The same target influenced cartilage regeneration after injury.
The cells did something unexpected
The cellular analysis provided the study’s most interesting clue. Using single-cell RNA sequencing and multiplexed imaging, the researchers identified different chondrocyte populations and tracked how they changed after 15-PGDH inhibition. Treatment reduced a population of 15-PGDH-positive chondrocytes associated with hypertrophic characteristics. At the same time, articular chondrocytes associated with extracellular-matrix synthesis became more prominent.
The researchers also did not see an increase in Ki67-positive chondrocytes, a marker of cell proliferation. Together, those observations support the interpretation that regeneration was driven mainly by changes in the gene-expression state of pre-existing chondrocytes, rather than by simply generating large numbers of new cells. That distinction could matter for regenerative medicine. Instead of supplying replacement cells, a treatment might potentially make the joint’s existing cells more capable of maintaining and rebuilding cartilage.
Human osteoarthritis cartilage responded
The researchers next tested PGDHi in human osteoarthritis cartilage explants obtained during total knee-replacement surgery. After seven days of laboratory treatment, the explants showed reduced 15-PGDH activity and increased sulfated glycosaminoglycan content. Treated tissue also showed increased stiffness in mechanical testing.
The experiments therefore showed that osteoarthritis cartilage from human joints retained a biological response to 15-PGDH inhibition under laboratory conditions. The human-tissue findings add an important layer to the animal results because the response involved cartilage affected by advanced human osteoarthritis rather than healthy tissue or an engineered substitute.
What could change in osteoarthritis treatment?
Today’s treatment pathway is largely about reducing symptoms, preserving function and managing progressive joint damage. A successful regenerative therapy would add a different goal: changing the biology of the cartilage so that the tissue itself contributes to repair. That could eventually move treatment from a model centered on managing cartilage loss toward one that also targets cartilage regeneration.
A painkiller can make a joint feel better without rebuilding its structure. A joint replacement can restore mechanical function by replacing damaged surfaces. A regenerative therapy would aim at the tissue between those two approaches: preserving the patient’s own joint by improving its capacity to repair itself. The 15-PGDH strategy is also different from cell-based approaches that introduce cartilage regeneration and or new cartilage-forming cells. Here, the key idea is to alter the behavior of cells that are already present.
The remaining development challenge
The research identifies a promising regenerative mechanism, but turning that mechanism into a human therapy will require solving the pharmacology and delivery problem. Articular cartilage is avascular, so small molecules generally reach mature cartilage by diffusion from synovial fluid. A 2026 analysis in Osteoarthritis and Cartilage Open noted that human cartilage is substantially thicker than mouse cartilage and that tissue geometry, matrix structure and joint-scale drug transport could affect how much of a compound reaches chondrocytes and for how long.
That issue is particularly relevant to SW033291 and future 15-PGDH inhibitors because biological activity in a model depends not only on the target itself but also on achieving adequate exposure at the target. The study’s authors also disclosed patent and licensing interests related to 15-PGDH inhibition and associated technologies, including licensing to Epirium Bio.
Why the finding matters
The most important idea emerging from this research is that aging cartilage may be more biologically flexible than its damaged appearance suggests. The researchers found that increasing 15-PGDH accompanies aging and injury, while blocking the enzyme shifted chondrocyte populations toward extracellular-matrix production and regenerated articular cartilage in mice. Human osteoarthritis cartilage regeneration showed corresponding biochemical and mechanical changes in laboratory experiments.
If subsequent development confirms that this pathway can be safely and effectively targeted in people, it could add something fundamentally different to the osteoarthritis toolbox: not simply controlling pain while a joint deteriorates, but using the joint’s own cells to help restore the tissue that has been damaged.
FAQs on potential cartilage regeneration treatment
Q: Can damaged cartilage regenerate naturally?
A: Articular cartilage has limited natural repair capacity, particularly after aging and osteoarthritis. The research discussed here suggests that changing the activity of existing chondrocytes may help restore cartilage tissue.
Q: What is 15-PGDH and why is it important for cartilage regeneration?
A: 15-PGDH is an enzyme involved in breaking down prostaglandins such as PGE2 and PGD2. Researchers found that its activity increased in aging and injured cartilage, while inhibiting it promoted cartilage regeneration in mice.
Q: Can osteoarthritis cartilage be regenerated without joint replacement?
A: The study points toward the possibility of regenerative treatment that could help damaged cartilage repair itself, potentially providing an approach between symptom management and joint replacement. The research is still at the experimental stage.
Q: How does the new cartilage regeneration treatment work?
A: The approach uses a small-molecule 15-PGDH inhibitor to alter the biological state of existing chondrocytes. In the mouse experiments, this shifted cartilage cells toward extracellular-matrix production and was associated with regenerated articular cartilage.
Q: Could 15-PGDH inhibitors become a treatment for osteoarthritis?
A: The findings identify 15-PGDH inhibition as a potential disease-modifying and regenerative approach to osteoarthritis. The treatment would need further development and testing to establish an effective clinical therapy for patients.
Q: How is cartilage regeneration different from current osteoarthritis treatments?
A: Most current osteoarthritis treatments focus on reducing pain, improving mobility and function, and managing joint damage, with joint replacement used for advanced disease. A regenerative approach would instead aim to improve the cartilage’s ability to maintain and rebuild itself.
Q: Did the cartilage regeneration treatment work in human tissue?
A: Researchers tested the 15-PGDH inhibitor on human osteoarthritis cartilage explants in the laboratory. After seven days, the tissue showed increased sulfated glycosaminoglycan content and stiffness, indicating a measurable regenerative response.
Q: Who could benefit from future cartilage regeneration treatments?
A: If this approach ultimately proves effective and safe in clinical development, it could potentially benefit people with osteoarthritis or cartilage damage who need more than symptom relief. The current research provides an experimental basis for that possibility rather than an available patient treatment.
Q: How much could a 15-PGDH cartilage regeneration treatment cost?
A: There is currently no approved 15-PGDH cartilage-regeneration treatment with an established patient price. Any future cost would depend on clinical development, regulatory approval, dosing, manufacturing and healthcare-system coverage.
Q: Can cartilage regeneration replace knee or hip replacement surgery?
A: A successful regenerative treatment could potentially delay or reduce the need for joint replacement in some patients by helping preserve damaged cartilage. Whether it could replace surgery for advanced osteoarthritis will depend on future clinical evidence and how much cartilage can be restored.
References
- Singla M, Wang YX, Monti E, Bedi Y, Agarwal P, Su S, Ancel S, Hermsmeier M, Devisetti N, Pandey A, Bakooshli MA. Inhibition of 15-hydroxy prostaglandin dehydrogenase promotes cartilage regeneration. Science. 2026 Mar 5;391(6789):1053-62. Doi: 10.1126/science.adx6649.
- Kingwell K. Promoting prostaglandin signalling for joint repair in osteoarthritis. nature reviews drug discovery. 2026 Feb 1;25:94-7. Doi: 10.1038/d41573-025-00209-5.
- Del Río E. Joint-scale transport considerations for translating 15-hydroxy prostaglandin dehydrogenase inhibition to cartilage regeneration. Osteoarthritis and Cartilage Open. 2026 Jun 1;8(2). Doi: 10.1016/j.ocarto.2026.100794.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Osteoarthritis: Diagnosis, Treatment, and Steps to Take. Accessed on Oct 09, 2026. Available from: https://www.niams.nih.gov/health-topics/osteoarthritis/diagnosis-treatment-and-steps-to-take
Disclaimer:
Some aspects of the preparation of this content may be assisted by artificial intelligence or automated technologies and are subject to human editorial review and source verification. Readers are encouraged to consult the original research and primary sources for complete context. External links are provided for convenience, and TheHonores does not control or endorse their content. Relevant conflicts of interest, funding, sponsorship, or other disclosures are identified where applicable. This content is for informational purposes only and is not professional or medical advice. Images are for illustrative or representational purposes unless otherwise stated. Photo by Gustavo Fring from Pexels.